Intrathecal Injection of Tigecycline and Polymyxin B in the Treatment of Extensively Drug-Resistant Intracranial Acinetobacter baumannii Infection: A Case Report and Review of the Literature

References

• Korinek AM, Baugnon T, Golmard JL. Risk factors for adult nosocomial meningitis after craniotomy: role of antibiotic prophylaxis. Neurosurgery. 2008.
   Web of Science ®Google Scholar
• Liu PF, Xu WH, Liu YL, et al. Analysis of 48 cases of intracranial infection after neurosurgery. J Binzhou Med Univ. 2011;34(3):3.
   Google Scholar
• Kourbeti IS, Jacobs AV, Koslow M, et al. Risk factors associated with postcraniotomy meningitis. Neurosurgery. 2007;60(2):317. doi:10.1227/01.NEU.0000249266.26322.25
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Galani L, Baziaka F, et al. Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review. Int J Antimicrob Agents. 2013;41(6):499–508. doi:10.1016/j.ijantimicag.2013.02.006
   PubMed Web of Science ®Google Scholar
• Lauretti L, D’Alessandris QG, Fantoni M, et al. First reported case of intraventricular tigecycline for meningitis from extremely drug-resistant Acinetobacter baumannii. J Neurosurg. 2016;127(2):1–4. doi:10.3171/2016.4.JNS16169
   Web of Science ®Google Scholar
• CHINET. Institute of Antibiotics, Huashan Hospital, Fudan University; 2020. Available from: http://www.chinets.com/Data/GermYear. Accessed March 15, 2022.
   Google Scholar
• De Bonis P, Lofrese G, Scoppettuolo G, et al. Intraventricular versus intravenous colistin for the treatment of extensively drug resistant Acinetobacter baumannii meningitis. Eur J Neurol. 2016;23(1):68–75. doi:10.1111/ene.12789
   PubMed Web of Science ®Google Scholar
• Shahbazi F, Dashti-Khavidaki S. Colistin: efficacy and safety in different populations. Expert Rev Clin Pharmacol. 2015;8(4):423–448.
   PubMed Web of Science ®Google Scholar
• Deng ZW, Wang J, Qiu CF, et al. A case report of intraventricular and intrathecal tigecycline infusions for an extensively drug-resistant intracranial Acinetobacter baumannii infection. Medicine. 2019;98(15):e15139. doi:10.1097/MD.0000000000015139
   Web of Science ®Google Scholar
• Cai Y, Lee W, Kwa AL. Polymyxin B versus colistin: an update. Expert Rev Anti Infect Ther. 2015;13(12):1481–1497. doi:10.1586/14787210.2015.1093933
   PubMed Web of Science ®Google Scholar
• Justo JA, Bosso JA. Adverse reactions associated with systemic polymyxin therapy. Pharmacotherapy. 2015;35(1):28–33. doi:10.1002/phar.1493
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Dimopoulos G, Poulakou G, et al. Task force on management and prevention of Acinetobacter baumannii infections in the ICU. Intensive Care Med. 2015;41(12):2057–2075. doi:10.1007/s00134-015-4079-4
   PubMed Web of Science ®Google Scholar
• Wu Y, Chen K, Zhao J, et al. Intraventricular administration of tigecycline for the treatment of multidrug-resistant bacterial meningitis after craniotomy: a case report. J Chemother. 2017;8:1.
   Google Scholar
• Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother. 2007;58(6):1221–1229. doi:10.1093/jac/dkl403
   Web of Science ®Google Scholar
• Kadoyama K, Sakaeda T, Tamon A, et al. Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system. Biol Pharm Bull. 2012;35(6):967. doi:10.1248/bpb.35.967
   PubMed Web of Science ®Google Scholar
• Tunkel AR, Rodrigo H, Adarsh B, et al. 2017 Infectious Diseases Society of America’s Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. Clin Infect Dis. 2017;6:701–706.
   Web of Science ®Google Scholar
• Kim BN, Peleg AY, Lodise TP, et al. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis. 2009;9(4):245–255. doi:10.1016/S1473-3099(09)70055-6
   PubMed Web of Science ®Google Scholar
• Huang CR, Chen SF, Lu CH, et al. Clinical characteristics and therapeutic outcomes of nosocomial super-infection in adult bacterial meningitis. BMC Infect Dis. 2011;11. doi:10.1186/1471-2334-11-133
   Web of Science ®Google Scholar
• Garnacho-Montero J, Timsit JF. Managing Acinetobacter baumannii infections. Curr Opin Infect Dis. 2019;32(1):69–76. doi:10.1097/QCO.0000000000000518
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother. 2014;15(10):1351–1370. doi:10.1517/14656566.2014.914172
   PubMed Web of Science ®Google Scholar
• Tullu MS, Dhariwal MS. Colistin: re-emergence of the “forgotten” antimicrobial agent. J Postgrad Med. 2013;59(3):208–215. doi:10.4103/0022-3859.118040
   Web of Science ®Google Scholar
• Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis. 2009;22(6):535–543. doi:10.1097/QCO.0b013e328332e672
   PubMed Web of Science ®Google Scholar
• Velkov T, Dai C, Ciccotosto GD, et al. Polymyxins for CNS infections: pharmacology and neurotoxicity. Pharmacol Ther. 2018;181:85–90. doi:10.1016/j.pharmthera.2017.07.012
   PubMed Web of Science ®Google Scholar
• Kim H-I, Kim S-W, Park G-Y, et al. The causes and treatment outcomes of 91 patients with adult nosocomial meningitis. Korean J Intern Med. 2012;27(2):171–179. doi:10.3904/kjim.2012.27.2.171
   PubMed Web of Science ®Google Scholar
• Alfahad WA, Omrani AS. Update on colistin in clinical practice. Saudi Med J. 2014;35(1):9–19.
   Web of Science ®Google Scholar
• Nang SC, Azad MAK, Velkov T, et al. Rescuing the last-line polymyxins: achievements and challenges. Pharmacol Rev. 2021;73(2):679–728. doi:10.1124/pharmrev.120.000020
   PubMed Web of Science ®Google Scholar
• Khawcharoenporn T, Apisarnthanarak A, Mundy LM. Intrathecal colistin for drug-resistant Acinetobacter baumannii central nervous system infection: a case series and systematic review. Clin Microbiol Infect. 2010;16(7):888–894. doi:10.1111/j.1469-0691.2009.03019.x
   PubMed Web of Science ®Google Scholar
• Bargiacchi O, Rossati A, Car P, et al. Intrathecal/intraventricular colistin in external ventricular device-related infections by multi-drug resistant Gram negative bacteria: case reports and review. Infection. 2014;42(5):801–809. doi:10.1007/s15010-014-0618-0
   PubMed Web of Science ®Google Scholar
• Blount JP, Campbell JA, Haines SJ. Complications in Ventricular Cerebrospinal Fluid Shunting. Neurosurg Clin N Am. 1993;4(4):633–656. doi:10.1016/S1042-3680(18)30556-4
   Google Scholar
• Ziaka M, Markantonis SL, Fousteri M, et al. Combined intravenous and intraventricular administration of colistin methanesulfonate in critically ill patients with central nervous system infection. Antimicrob Agents Chemother. 2013;57(4):1938–1940. doi:10.1128/AAC.01461-12
   PubMed Web of Science ®Google Scholar
• Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10–39. doi:10.1002/phar.2209
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kasiakou SK. Use of international units when dosing colistin will help decrease confusion related to various formulations of the drug around the world. Antimicrob Agents Chemother. 2006;50(6):2274–2275. doi:10.1128/AAC.00101-06
   Web of Science ®Google Scholar
• Nation RL, Li J, Cars O, et al. Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin Infect Dis. 2014;58(1):139–141. doi:10.1093/cid/cit680
   PubMed Web of Science ®Google Scholar
• Pan S, Huang X, Wang Y, et al. Correction to: efficacy of intravenous plus intrathecal/intracerebral ventricle injection of polymyxin B for post-neurosurgical intracranial infections due to MDR/XDR Acinectobacter baumannii: a retrospective cohort study. Antimicrob Resist Infect Control. 2019;8(1). doi:10.1186/s13756-019-0462-1
   Web of Science ®Google Scholar
• Xing H, Cheng C, Zhang Y, et al. Successful treatment with intrathecal and intravenous Polymyxin B-Based combination against MDR Acinetobacter baumannii meningitis in pediatric patient: a Case Report. Front Pediatr. 2021;9:564991. doi:10.3389/fped.2021.564991
   PubMed Web of Science ®Google Scholar
• Zhong L, Shi XZ, Su L, et al. Sequential intraventricular injection of tigecycline and polymyxin B in the treatment of intracranial Acinetobacter baumannii infection after trauma: a case report and review of the literature. Military Med Res. 2020;7. doi:10.1186/s40779-020-00253-9
   Web of Science ®Google Scholar
• Guo W, Guo SC, Li M, et al. Successful treatment of extensively drug-resistant Acinetobacter baumannii ventriculitis with polymyxin B and tigecycline- A case report. Antimicrob Resist Infect Control. 2018;7:22. doi:10.1186/s13756-018-0313-5
   Web of Science ®Google Scholar
• Chen H, Guo X, Xie D, et al. A clinical study on the use of intraventricular Polymyxin B supplemented by continuous external ventricular drainage in the treatment of drug-resistant gram-negative bacilli intracranial infection. Infect Drug Resist. 2020;13:2963–2970. doi:10.2147/IDR.S261510
   Web of Science ®Google Scholar
• Sun X, Zhang Y, Zhang L, et al. Long course of polymyxin B for the treatment of brain abscess caused by carbapenem resistant Acinetobacter baumannii: a case report. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021;33(11):1370–1372. doi:10.3760/cma.j.cn121430-20210326-00452
   Google Scholar
• Ye J, Tan LH, Shen ZP, et al. Polymyxin for the treatment of intracranial infections of extensively drug-resistant bacteria in children after neurosurgical operation. World J Pediatr. 2020;16(5):528–532. doi:10.1007/s12519-020-00350-8
   PubMed Web of Science ®Google Scholar
• Pankey GA. Tigecycline. J Antimicrob Chemother. 2005;56(3):470–480. doi:10.1093/jac/dki248
   PubMed Web of Science ®Google Scholar
• Abdallah M, Alsaleh H, Baradwan A, et al. Intraventricular tigecycline as a last resort therapy in a patient with difficult-to-treat healthcare-associated Acinetobacter baumannii ventriculitis: a Case Report. SN Compr Clin Med. 2020;2(9):1683–1687. doi:10.1007/s42399-020-00433-7
   Google Scholar
• Li LM, Zheng WJ, Shi SW. Spinal arachnoiditis followed by intrathecal tigecycline therapy for central nervous system infection by extremely drug-resistant Acinetobacter baumannii.. J Int Med Res. 2020;48(7):300060520920405. doi:10.1177/0300060520920405
   Web of Science ®Google Scholar
• Liu Y, Pu Z, Zhao M. Case report of successful treatment of extensively drug-resistant Acinetobacter baumannii Ventriculitis with intravenous plus intraventricular tigecycline. Antimicrob Agents Chemother. 2018;62(11):e01625–18. doi:10.1128/AAC.01625-18
   Web of Science ®Google Scholar
• Li W, Li DD, Yin B, et al. Successful treatment of pyogenic ventriculitis caused by extensively drug-resistant Acinetobacter baumannii with multi-route tigecycline: a case report. World J Clin Cases. 2021;9(3):651–658. doi:10.12998/wjcc.v9.i3.651
   Web of Science ®Google Scholar
• Fang YQ, Zhan RC, Jia W, et al. A case report of intraventricular tigecycline therapy for intracranial infection with extremely drug resistant Acinetobacter baumannii. Medicine. 2017;96(31):e7703. doi:10.1097/MD.0000000000007703
   Web of Science ®Google Scholar
• Wang L, Zhang J, Yu X, et al. Intrathecal injection of tigecycline in treatment of multidrug-resistant Acinetobacter baumannii meningitis: a case report. Eur J Hosp Pharm. 2017;24(3):182–184. doi:10.1136/ejhpharm-2016-000972
   Google Scholar
• Guangqiong YU, Zou Y, Liu H, et al. Synergistic effect of a combination of colistin and tigecycline against multidrug-resistant Acinetobacter baumannii. Drug Eval Res. 2018;54:e34.
   Google Scholar
• Qu J, Yu R, Wang Q, et al. Synergistic antibacterial activity of combined antimicrobials and the clinical outcome of patients with carbapenemase-producing Acinetobacter baumannii infection. Front Microbiol. 2020;11:541423. doi:10.3389/fmicb.2020.541423
   PubMed Web of Science ®Google Scholar